Matinas BioPharma Holdings, Inc.

Enabling the Delivery of Life-Changing Medicines

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology.

Learn More About Our LNC Platform

About Matinas Biopharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable.

about matinas biopharma »

Drug Pipeline

Candidate & Indication Development Stage
IND Preparation Phase 1 Development Phase 2 Development Phase 3 Development Market
MAT2203 Prevention of IFI in Acute Lymphoblastic Leukemia
IND Preparation Phase complete
Phase 1 Development Phase complete
Phase 2 Development Phase in progress
Phase 3 Development Phase not started
Market Phase not started
MAT2501 Non-Tuberculous Mycobacterium (NTM) Infections
IND Preparation Phase complete
Phase 1 Development Phase in progress
Phase 2 Development Phase not started
Phase 3 Development Phase not started
Market Phase not started

MAT9001

MAT9001 is a next generation, prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia (TG>500 mg/dL), which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, total- and non-HDL-cholesterol, apolipoproteins and PCSK9 levels.

Candidate & Indication Development Stage
Discovery IND Preparation Early Clinical Development Phase 3 Development Market
MAT9001 Hypertriglyceridemia
Discovery Phase complete
IND Preparation Phase complete
Early Clinical Development Phase in progress
Phase 3 Development Phase not started
Market Phase not started